Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises BICO in conjunction with directed share issue worth MSEK 487 to Sartorius
Mandate

Vinge advises BICO in conjunction with directed share issue worth MSEK 487 to Sartorius

December 09, 2022 Capital Markets and Public M&A Life Sciences & Health

Vinge has advised BICO Group AB in connection with a directed share issue to Sartorius AG, adding a total amount of MSEK 487 to BICO. The subscription price of SEK 76 was equivalent to a premium of 2.7 per cent compared with a 3-day VWAP. In connection with the share issue, BICO and Sartorius have entered into an extensive co-operation agreement concerning technical, sales and marketing issues.

Vinge’s team consisted of Anders Strid, Edin Agic and company registrations assistant Daniela Maniscalchi.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026